OP0266 Lysophophatidic Acid Receptor 1 Antagonist SAR100842 as a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2A Study

BackgroundPreclinical genetic and pharmacological studies suggest a role for Lysophosphatidic acid (LPA) in the three key processes characterizing systemic sclerosis (SSc): fibrosis, microangiopathy and immunoinflammation.ObjectivesWe have assessed SAR100842, a potent orally available selective antagonist of the LPA1 receptor and explored safety, skin biomarkers of LPA pathway, and clinical efficacy in patients with early diffuse cutaneous SSc (dcSSc) in a phase 2a clinical trial.MethodsACT12339, study NCT01651143 sponsored by SANOFI, was an 8-week double-blind, randomized, placebo-controlled study followed by a 16 week open label extension study with SAR100842. 32 patients with dcSSc